Biktarvy Tablet
NDC Package 50090-6247-0
Package Information
Biktarvy (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate) tablets is bIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg:who have no antiretroviral treatment history orto replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir. This formulation utilizes a tablet delivery system. Marketed by A-s Medication Solutions, this product is identified by NDC 50090-6247 and is authorized under FDA application NDA210251.
Identification & Billing
- RxCUI: 1999667 - bictegravir 50 MG / emtricitabine 200 MG / tenofovir alafenamide 25 MG Oral Tablet
- RxCUI: 1999667 - bictegravir 50 MG (as bictegravir sodium 52.5 MG) / emtricitabine 200 MG / tenofovir alafenamide 25 MG (as tenofovir alafenamide fumarate 28 MG) Oral Tablet
- RxCUI: 1999673 - Biktarvy 50 MG / 200 MG / 25 MG Oral Tablet
- RxCUI: 1999673 - bictegravir 50 MG / emtricitabine 200 MG / tenofovir alafenamide 25 MG Oral Tablet [Biktarvy]
Clinical Specifications
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Nucleoside Reverse Transcriptase Inhibitors - [MoA] (Mechanism of Action)
- Nucleosides - [CS]
Regulatory & Marketing
Hierarchy Structure
- 50090 - A-s Medication Solutions
- 50090-6247 - Biktarvy
- 50090-6247-0 - 30 TABLET in 1 BOTTLE, PLASTIC
- 50090-6247 - Biktarvy
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50090-6247-0 identifies a specific commercial package of 30 tablet in 1 bottle, plastic of Biktarvy, a human prescription drug labeled by A-s Medication Solutions. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This tablet is formulated for oral use and contains bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by A-s Medication Solutions on February 07, 2018. The current certification is valid through December 31, 2026.
How is this A-s Medication Solutions product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50090624700. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.